AKUMS
DRUGS & PHARMACEUTICALS LTD.

Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2026-27/69 November 28, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 544222

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Final Order on Writ Petition

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 **("SEBI LODR Regulations")**, this is to inform you that Akums Lifesciences Limited ("ALL"), now merged with Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of Akums Drugs and Pharmaceuticals Limited **("the Company")** has received an order from the High Court of Punjab & Haryana at Chandigarh on November 26, 2026, quashing the assessment order, demand and penalty notice issued by the Deputy Commissioner of Income Tax, Chandigarh (DCIT) dated September 26, 2021, for the assessment year 2017-18 i.e. period prior to the acquisition of ALL (earlier known as "Parabolic Drugs Limited"), through the Corporate Insolvency Resolution Process in terms of the Insolvency and Bankruptcy Code, 2016.

It is hereby further informed that as the final order from the High Court of Punjab & Haryana at Chandigarh has been received, the Company now onwards is not required to provide further updates on the aforesaid tax litigation to the Stock Exchanges, which was being disclosed earlier on quarterly basis through Integrated Filing (Governance), in terms of sub-para 8 of para B of Part A of Schedule III read with Annexure 18 of the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 **("Master Circular")**.

The details required to be furnished under Regulation 30 of SEBI LODR Regulations read with Master Circular is annexed as **"Annexure-A"**.

The above-mentioned order was received by the Company on November 28, 2026 at 10:50 A.M.

A copy of this disclosure is being updated on the website of the Company at www.akums.in

This is for your information and records.

Thanking You

Yours Faithfully
For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.11.28 15:44:40 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As above

AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000
CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Annexure – A

Details pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	the details of any change in the status and / or any development in relation to such proceedings;	The Hon'ble High Court of Punjab & Haryana at Chandigarh, vide its final order dated 26.11.2026, has allowed the writ petition having reference CWP-23400-2021 (AY 2017-18) filed by Akums Lifesciences Limited (PAN: AACCP1419K) [now merged with Pure and Cure Healthcare Private Limited (PAN: AAECP0713G)] and set aside the assessment order u/s 144, notice of demand u/s 156 (Rs. 73,44,62,070/-) and penalty notice u/s 274 read with section 270A, all dated 26.09.2021 of Deputy Commissioner of Income Tax, Chandigarh (DCIT), on the basis of the Division Bench judgment in H L Buildwell Pvt. Ltd. vs. DCIT (CWP-37049-2025) dated 06.05.2026
2.	in the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings;	N.A.
3.	in the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.	N.A.